Effects of dexmedetomidine on perioperative coagulation function and inflammatory factors in patients with malignant ovarian tumors / 肿瘤研究与临床

ABSTRACT

Objective:To investigate the effects of dexmedetomidine on perioperative coagulation function and inflammatory factors in patients with malignant ovarian tumors.Methods:A total of 60 patients undergoing cytoreductive surgery for malignant ovarian tumors from September 2019 to May 2020 in the Second Hospital of Shanxi Medical University were selected and divided into the dexmedetomidine group and the control group according to the random number table method, 30 cases in each group. Patients in the dexmedetomidine group were pumped with dexmedetomidine 0.5 μg/kg 10 min before induction of anesthesia, and then the intravenous pump was maintained at a rate of 0.2-0.6 μg·kg -1·h -1 until 30 min before the completion of the operation pump injection. The control group was pumped with 0.9% NaCl solution of the same volume at the same time. Before induction of anesthesia (T 0), 2 h after administration (T 1), and 3 h after operation (T 2), the patients' venous blood was collected to detect platelet count (Plt), prothrombin time (PT), activated partial thrombin time (APTT), plasma fibrinogen (FIB), D-dimer; and levels of serum inflammatory factors interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α) were also detected. The operation time, intraoperative fluid infusion, amount of anesthetics, and total intraoperative blood loss were compared between the two groups. Results:Plt at T 1 and T 2 time were (154±28)×10 9/L, (138±27)×10 9/L of the dexmedetomidine group and (133±44)×10 9/L, (114±50)×10 9/L of the control group, which were lower than those of both groups at T 0 time [(182±46)×10 9/L, (184±55)×10 9/L], and the differences were statistically significant ( F values were 11.975, 16.058, all P < 0.05); and Plt at T 1 and T 2 time of the control group were lower than those of the dexmedetomidine group (all P < 0.05). FIB level at T 1 and T 2 time [(3.2±0.9) g/L, (3.3±0.9) g/L of the dexmedetomidine group; (3.7±0.6) g/L, (4.6±0.9) g/L of the control group] and D-dimer level at T 1 and T 2 time [(0.77±0.25) mg/L, (0.81±0.51) mg/L of the dexmedetomidine group; (0.96±0.31) mg/L, (1.15±0.56) mg/L of the control group] were higher than those of both groups at T 0 time [FIB (3.0met) g/L, (2.8 met) g/L; D-dimer (0.65rt T) mg/L, (0.63 rt T) mg/L], and the differences were statistically significant (F values were 5.234, 46.121, 4.358, 11.091, all P < 0.05); FIB and D-dimer levels at T 1 and T 2 time of the control group were higher than those of the dexmedetomidine group (all P < 0.05). PT and APTT at T 2 time of the dexmedetomidine group were (12.7±0.5) s and (33.8±3.7) s, respectively, and the control group were (12.3±0.8) s, (31.8±2.4)s, respectively, which were shorter than those of both groups at T 0 time [PT (13.0±0.3) s, (13.0±0.3) s; APTT (35.7±2.0) s, (35.7±2.6) s], and the differences were statistically significant (all P < 0.05), and PT and APTT levels at T 2 time of the control group were shorter than those of the dexmedetomidine group (all P < 0.05). IL-6 level at T 1 and T 2 time [(73.3±2.8) pg/L, (84.7±3.8) pg/L of the dexmedetomidine group; (81.5±3.6) pg/L, (89.8±3.2) pg/L of the control group] and TNF-α level at T 1 and T 2 time [(27.4±4.4) ng/L, (32.9±3.7) ng/L of the dexmedetomidine group; (32.7±2.5) ng/L, (39.8±4.0) ng/L of the control group] were higher than those of both groups at T 0 time [IL-6 (65.9±2.9) pg/L, (65.0±1.8) pg/L; TNF-α (15.4±3.1) ng/L, (16.6±2.6) ng/L)], and the differences were statistically significant ( F values were 264.650, 553.019, 162.447, and 438.225, respectively, all P < 0.05), and IL-6 and TNF-α levels at T 1 and T 2 time of the control group were higher than those of the dexmedetomidine group (all P < 0.05). There were no statistically significant differences in operation time, intraoperative fluid infusion, and intraoperative total blood loss between the two groups (all P > 0.05), but the intraoperative use of propofol and remifentanil of the control group was more than that of the dexmedetomidine group (all P < 0.05). Conclusion:Dexmedetomidine under general anesthesia for malignant ovarian patients undergoing surgery can effectively improve the perioperative coagulation function and reduce the level of inflammatory factors, thereby reducing the risk of postoperative thrombotic events.